EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
13.66
+0.25 (1.86%)
May 8, 2026, 4:00 PM EDT - Market closed
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$35,579
Profits / Employee
-$1,269,154
Market Cap
1.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | 49 | 29.70% | 214 | 0 |
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 435 |
| Zenas BioPharma | 167 |
| MapLight Therapeutics | 133 |
| Septerna | 130 |
| MoonLake Immunotherapeutics | 130 |
| DBV Technologies | 117 |
| Inventiva | 77 |
EYPT News
- 2 days ago - EyePoint reports Q1 EPS (99c), consensus (81c) - TheFly
- 3 days ago - EyePoint Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 10 days ago - EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - GlobeNewsWire
- 23 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference - Transcripts
- 7 weeks ago - EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
- 7 weeks ago - EyePoint reports inducement grants under NASDAQ listing rule - TheFly